Drug intelligence / Profile preview

177Lu-9E7.4

Development stage: Preclinical
Lead developer: Inserm
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-9E7.4 is a radioimmunotherapy (RIT) agent currently under investigation for the treatment of multiple myeloma. It consists of the murine monoclonal antibody 9E7.4, which specifically targets the CD138 (syndecan-1) antigen, a protein highly expressed on the surface of malignant plasma cells. The antibody is conjugated to Lutetium-177 (177Lu), a radioisotope that emits beta particles with a maximum energy of 0.5 MeV and a half-life of 6.7 days. This allows for the delivery of targeted cytotoxic radiation directly to tumor cells, causing double-stranded DNA breaks and subsequent apoptosis. Developed primarily by research teams in Nantes, France (including INSERM and the University of Nantes), 177Lu-9E7.4 has been evaluated in preclinical models to compare its therapeutic efficacy against alpha-emitting isotopes like Bismuth-213, aiming to optimize radioimmunotherapy strategies for hematologic malignancies.

Other names: Lutetium-177-labeled anti-CD138 antibody 9E7.4Lutetium177-labeled anti-CD138 antibody 9E7.4Lutetium 177-labeled anti-CD138 antibody 9E7.4177Lu-anti-CD138177Lu-DOTA-9E7.4

Targets

SDC1 (Syndecan-1)

Beyond the preview

Go deeper on 177Lu-9E7.4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-9E7.4.

Explore the full profile